| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.43 | 53.07 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 12.18B | 45.44 | 25.82 | 18.49% | 29.63% | 31.37% | 5.2% | 0.09 |
| BBOTBridgeBio Oncology Therapeutics Inc. | 919.87M | 11.50 | 25 | -25.73% | ||||
| INBXInhibrx Biosciences, Inc. | 1.04B | 71.80 | 0.62 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.1B | 6.14 | -2.91 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.32B | 7.63 | -3.23 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 1.12B | 11.52 | -6.30 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.09B | 18.82 | -7.24 | 49.59% | -46.83% | -27.21% | 0.18 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 583.23K | 1.5M |
| Revenue Growth % | - | - | - | - | - | - | - | 1.58% |
| Cost of Goods Sold | 7.93K | 8.32K | 170.25K | 229.61K | 271.68K | 16.4M | 7.05K | 9.36M |
| COGS % of Revenue | - | - | - | - | - | - | 0.01% | 6.23% |
| Gross Profit | -7.93K | -8.32K | -170.25K | -229.61K | -271.68K | -16.4M | 576.18K | -7.86M |
| Gross Margin % | - | - | - | - | - | - | 0.99% | -5.23% |
| Gross Profit Growth % | - | -0.05% | -19.47% | -0.35% | -0.18% | -59.37% | 1.04% | -14.64% |
| Operating Expenses | 15.85M | 16.49M | 29.37M | 52.81M | 37.17M | 96.99M | 16.05M | 6.46M |
| OpEx % of Revenue | - | - | - | - | - | - | 27.52% | 4.3% |
| Selling, General & Admin | 2.46M | 2.29M | 8.42M | 14.93M | 13.55M | 20.97M | 8.42M | 6.46M |
| SG&A % of Revenue | - | - | - | - | - | - | 14.44% | 4.3% |
| Research & Development | 13.39M | 14.19M | 20.95M | 37.88M | 23.9M | 92.42M | 7.63M | 9.36M |
| R&D % of Revenue | - | - | - | - | - | - | 13.08% | 6.23% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | -271.68K | -16.4M | 0 | -9.36M |
| Operating Income | -15.85M | -16.49M | -29.54M | -52.81M | -37.45M | -113.39M | -15.47M | -14.32M |
| Operating Margin % | - | - | - | - | - | - | -26.53% | -9.53% |
| Operating Income Growth % | - | -0.04% | -0.79% | -0.79% | 0.29% | -2.03% | 0.86% | 0.07% |
| EBITDA | -15.84M | -16.48M | -29.37M | -52.58M | -37.17M | -113.39M | -15.46M | -14.3M |
| EBITDA Margin % | - | - | - | - | - | - | -26.52% | -9.52% |
| EBITDA Growth % | - | -0.04% | -0.78% | -0.79% | 0.29% | -2.05% | 0.86% | 0.08% |
| D&A (Non-Cash Add-back) | 7.93K | 8.32K | 170.25K | 229.61K | 271.68K | 4.4K | 7.05K | 22.32K |
| EBIT | -15.19M | -15.53M | -28.06M | -53.48M | -37.13M | -37.37M | -14.29M | -14.32M |
| Net Interest Income | 0 | 0 | -156.35K | 0 | 1.65K | 0 | 1.22M | 1.29M |
| Interest Income | 0 | 0 | 0 | 222.65K | 1.65K | 448.67K | 1.22M | 1.29M |
| Interest Expense | 15 | 182 | 156.35K | 222.65K | 0 | 448.67K | 0 | 0 |
| Other Income/Expense | 662.13K | 961.13K | 1.48M | -667.6K | 319.05K | 730.2K | 1.19M | 1.36M |
| Pretax Income | -15.19M | -15.53M | -28.06M | -53.48M | -37.13M | -112.66M | -14.29M | -12.96M |
| Pretax Margin % | - | - | - | - | - | - | -24.5% | -8.62% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1.01% | 0.98% | 1% | 1% | 1% |
| Net Income | -15.19M | -15.53M | -28.06M | -53.92M | -36.54M | -112.66M | -14.29M | -12.96M |
| Net Margin % | - | - | - | - | - | - | -24.5% | -8.62% |
| Net Income Growth % | - | -0.02% | -0.81% | -0.92% | 0.32% | -2.08% | 0.87% | 0.09% |
| Net Income (Continuing) | -15.19M | -15.53M | -28.06M | -53.48M | -37.13M | -112.66M | -14.29M | -12.96M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -21.58 | -22.06 | -26.28 | -50.61 | -34.88 | -1359.79 | -3.95 | -2.35 |
| EPS Growth % | - | -0.02% | -0.19% | -0.93% | 0.31% | -37.98% | 1% | 0.41% |
| EPS (Basic) | -21.58 | -22.06 | -26.28 | -50.61 | -34.88 | -1359.79 | -3.95 | -2.35 |
| Diluted Shares Outstanding | 703.78K | 703.78K | 1M | 1.06M | 1.06M | 82.85K | 3.62M | 5.51M |
| Basic Shares Outstanding | 703.78K | 703.78K | 1M | 1.06M | 1.06M | 82.85K | 3.62M | 5.51M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 24.73M | 66M | 133.04M | 92.42M | 56.58M | 30.15M | 22.52M | 23.58M |
| Cash & Short-Term Investments | 24.4M | 65.68M | 130.09M | 89.02M | 53.08M | 28.79M | 21.61M | 22.85M |
| Cash Only | 24.4M | 65.68M | 130.09M | 89.02M | 53.08M | 28.79M | 21.61M | 22.85M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 1.37M | 914.27K | 726.25K |
| Total Non-Current Assets | 30.46K | 24.56K | 563.14K | 388.51K | 239.05K | 2.32K | 129.08K | 403.35K |
| Property, Plant & Equipment | 30.34K | 24.45K | 563.03K | 359.13K | 209.68K | 2.32K | 88.36K | 81.52K |
| Fixed Asset Turnover | - | - | - | - | - | - | 6.60x | 18.43x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 40.72K | 40.17K |
| Other Non-Current Assets | 121 | 111 | 107 | 29.38K | 29.37K | 0 | 0 | 281.66K |
| Total Assets | 24.76M | 66.02M | 133.61M | 92.81M | 56.82M | 30.16M | 22.65M | 23.98M |
| Asset Turnover | - | - | - | - | - | - | 0.03x | 0.06x |
| Asset Growth % | - | 1.67% | 1.02% | -0.31% | -0.39% | -0.47% | -0.25% | 0.06% |
| Total Current Liabilities | 4.3M | 4.87M | 9.06M | 15.33M | 7.32M | 3.2M | 4.39M | 3.36M |
| Accounts Payable | 1.66M | 1.74M | 2.18M | 4.5M | 1.77M | 842.75K | 1.67M | 1.35M |
| Days Payables Outstanding | 76.47K | 76.34K | 4.67K | 7.16K | 2.38K | 18.75 | 86.46K | 52.71 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 528.97K | 0 |
| Other Current Liabilities | 1.92M | 2.5M | 961.79K | 1.52M | 1.42M | 960.36K | 1.17M | 465.01K |
| Current Ratio | 5.75x | 13.56x | 14.68x | 6.03x | 7.73x | 9.42x | 5.14x | 7.01x |
| Quick Ratio | 5.75x | 13.56x | 14.68x | 6.03x | 7.73x | 9.42x | 5.14x | 7.01x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 56.23M | 112.59M | 302.62K | 78.85K | 0 | 1.31M | 1.31M | 1.31M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 302.62K | 78.85K | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 56.23M | 112.59M | 0 | 0 | 0 | 1.31M | 1.31M | 1.31M |
| Total Liabilities | 60.53M | 117.46M | 9.36M | 15.41M | 7.32M | 4.51M | 4.39M | 4.67M |
| Total Debt | 0 | 0 | 544.95K | 335.16K | 190.47K | 0 | 0 | 0 |
| Net Debt | -24.4M | -65.68M | -129.54M | -88.68M | -52.89M | -28.79M | -21.61M | -22.85M |
| Debt / Equity | - | - | 0.00x | 0.00x | 0.00x | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | -999999.00x | -90601.12x | -188.96x | -237.19x | - | -252.73x | - | - |
| Total Equity | -35.77M | -51.44M | 124.24M | 77.4M | 49.51M | 25.64M | 18.26M | 19.31M |
| Equity Growth % | - | -0.44% | 3.42% | -0.38% | -0.36% | -0.48% | -0.29% | 0.06% |
| Book Value per Share | -50.82 | -73.09 | 123.64 | 73.24 | 46.51 | 309.51 | 5.05 | 3.50 |
| Total Shareholders' Equity | -35.77M | -51.44M | 124.24M | 77.4M | 49.51M | 25.64M | 18.26M | 19.31M |
| Common Stock | 126.84K | 127.09K | 21.02K | 21.19K | 1.09K | 2.65K | 3.74K | 5.48K |
| Retained Earnings | -46.94M | -62.47M | -90.53M | -144.01M | -181.13M | -293.8M | -308.08M | -321.04M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -8.29M | -8.76M | -11.53M | -10.04M | -10.36M | -10.62M | -10.61M | -10.63M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -14M | -15.25M | -26.71M | -41.8M | -37.69M | -25.01M | -12.18M | -13.56M |
| Operating CF Margin % | - | - | - | - | - | - | -20.88% | -9.02% |
| Operating CF Growth % | - | -0.09% | -0.75% | -0.57% | 0.1% | 0.34% | 0.51% | -0.11% |
| Net Income | -15.19M | -15.53M | -28.06M | -53.48M | -37.13M | -112.66M | -14.29M | -12.96M |
| Depreciation & Amortization | 7.93K | 8.32K | 170.25K | 229.61K | 271.68K | 186.44K | 7.05K | 22.32K |
| Stock-Based Compensation | 395.44K | 329.18K | 1.35M | 4.98M | 7.81M | 16.98M | 444.46K | 489.44K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -662.14K | -961.32K | -1.33M | 890.25K | -317.4K | 72.24M | 38.93K | -54.37K |
| Working Capital Changes | 1.45M | 901.85K | 1.16M | 5.57M | -8.33M | -1.76M | 1.62M | -1.06M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 327.05K | 214.38K | 437.51K | 2.33M | -2.73M | -858.51K | 827.46K | -314.21K |
| Cash from Investing | 0 | -3.7K | -30.9K | -25.71K | 0 | 0 | -93.09K | -15.48K |
| Capital Expenditures | 0 | -3.7K | -30.9K | -25.71K | 0 | 0 | -93.09K | -15.48K |
| CapEx % of Revenue | - | - | - | - | - | - | 0.16% | 0.01% |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 23.34M | 56.37M | 92.58M | 150.95K | 1.75M | 682.97K | 5.14M | 14.82M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 0 | 2.1K | 71K | 0 | 208.37K | 0 | -648.93K | -1.32M |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | -14M | -15.25M | -26.74M | -41.83M | -37.69M | -25.01M | -12.27M | -13.57M |
| FCF Margin % | - | - | - | - | - | - | -21.04% | -9.03% |
| FCF Growth % | - | -0.09% | -0.75% | -0.56% | 0.1% | 0.34% | 0.51% | -0.11% |
| FCF per Share | -19.90 | -21.67 | -26.61 | -39.58 | -35.41 | -301.88 | -3.39 | -2.46 |
| FCF Conversion (FCF/Net Income) | 0.92x | 0.98x | 0.95x | 0.78x | 1.03x | 0.22x | 0.85x | 1.05x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -77.08% | -53.48% | -57.58% | -299.83% | -65.08% | -68.98% |
| Gross Margin | - | - | - | - | - | - | 98.79% | -523.16% |
| Net Margin | - | - | - | - | - | - | -2449.59% | -862.43% |
| Debt / Equity | - | - | 0.00x | 0.00x | 0.00x | - | - | - |
| Interest Coverage | -999999.00x | -90601.12x | -188.96x | -237.19x | - | -252.73x | - | - |
| FCF Conversion | 0.92x | 0.98x | 0.95x | 0.78x | 1.03x | 0.22x | 0.85x | 1.05x |
| Revenue Growth | - | - | - | - | - | - | - | 157.63% |
Aprea Therapeutics, Inc. (APRE) reported $0.5M in revenue for fiscal year 2024.
Aprea Therapeutics, Inc. (APRE) grew revenue by 157.6% over the past year. This is strong growth.
Aprea Therapeutics, Inc. (APRE) reported a net loss of $13.0M for fiscal year 2024.
Aprea Therapeutics, Inc. (APRE) has a return on equity (ROE) of -69.0%. Negative ROE indicates the company is unprofitable.
Aprea Therapeutics, Inc. (APRE) had negative free cash flow of $13.5M in fiscal year 2024, likely due to heavy capital investments.